Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)

NTM-PD is becoming an increasingly prevalent disease in the United States and in many places in the world.

How do you recognize and diagnose it? What are the basic tenets of treatment?

CLINICAL PRESENTATION

Fever
Weight Loss
Cough
Shortness of Breath

Radiographic Patterns or Clinical Phenotypes

Fibronodular Bronchiectasis (Often in post-menopausal women)
- Nodular and small centrilobular nodules or tree-in-bud opacities
- Bronchiectasis with right middle lobe and lingular predominance

Fibrocavitary (Often coexisting emphysema in men)
- Upper lobe predominant cavitary
- Adjacent ground glass +/- micronodules

Hypersensitivity Pneumonitis ("Hot tub lung")
- Diffuse ill-defined centrilobular nodules with ground glass
- Associated with inhalation exposure (eg, MAC from hot tub)

ATRS/ERS/ESCMID/IDSA Diagnostic Criteria (All three criteria required and exclusion of alternative diagnosis)

Clinical Features
Pulmonary or systemic symptoms (as above)

Radiographic Changes
Nodular or cavitary lung opacities on chest imaging, or Chest CT showing bronchiectasis with multiple small nodules (tree-in-bud appearance)

Microbiology
Positive sputum culture results from >2 samples, or Positive bronchial wash or BAL culture, or Transbronchial/lung biopsy with mycobacterial histologic features and positive culture for NTM, or Biopsy showing mycobacterial histologic features and >1 sputum or bronchial culture positive for NTM

Treatment Pearls for M. Avium Complex (MAC) Lung Disease

- Typically includes a three-drug regimen based on drug-susceptibilities for macrolide and amikacin; consider consultation with specialist
- Duration: At least 12 months after sputum culture conversion
  - Macrolide (Azithromycin preferred) + Rifamycin + Ethambutol
  - Cavitary/severe disease/macrolide-resistance → add IV amikacin or streptomycin and daily oral antimicrobial therapy
  - No response after treatment for 6 months (probable refractory MAC lung disease) → consider adding inhaled liposomal amikacin

© 2021 American College of Chest Physicians